Deferoxamine Mesylate Injection, Powder, Lyophilized, For Solution
Product Images NDC 60505-6237

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Deferoxamine Mesylate (NDC 60505-6237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2gm-vial (2gm Vial)

Label for Deferoxamine Mesylate for Injection, USP 2 g per vial, powder for solution injection. The label indicates use for subcutaneous, intramuscular, or intravenous administration and single-dose use. Manufactured by Gland Pharma Limited in India and labeled for Apotex Corp. The label includes storage instructions, barcode, and a note regarding reconstitution expiration and disposal of unused portions.*

FDA Label Image

500mg-vial (500mg Vial)

Label for Deferoxamine Mesylate for Injection, USP, 500 mg per vial in lyophilized powder form. It indicates use for subcutaneous, intramuscular, or intravenous injection. The label identifies Apotex Corp. as the labeler and Gland Pharma Limited, Hyderabad, India as manufacturer, with storage instructions and barcode details.*

FDA Label Image

Deferoxamine01 (Deferoxamine01)

Chemical structure of deferoxamine mesylate, showing its molecular composition as displayed in a structural formula diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.